Adnexus Therapeutics Announces Issuance of U.S. Patent for Broad Protection of New Therapeutic Class, Adnectins(TM).WALTHAM, Mass. -- Adnexus Therapeutics(TM), Inc. announced today that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property (USPTO USPTO abbr. United States Patent and Trademark Office ) has granted U.S. Patent No. 7,115,396 with broad composition of matter claims to Adnectin(TM) proteins. Exclusively owned by Adnexus, this patent further expands the company's ownership of Adnectins, a class of targeted biologics with broad applicability across many aspects of the biotechnology industry, including both therapeutics and diagnostics. "The new biologics landscape is a rapidly evolving area of the pharmaceutical industry. Leading companies recognize the importance of a strong, clear intellectual property position in biologics," said John D. Mendlein, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Adnexus. "We have a unique opportunity to create valuable products with attractive IP profiles, compared to antibody, antibody-fragment, and siRNA based products. Our strategic consolidation and advancement of intellectual property for both the Adnectin product class and for PROfusion, our proprietary discovery engine, permits industry unique pipeline building in markets that have historically been inaccessible due to the blocking IP positions of traditional product forms. This new patent deepens our ability to protect new Adnectin-based medicines as well as other kinds of Adnectin products." Adnexus is the exclusive developer of Adnectins. Adnexus solely owns the Adnectin patent estate that controls issued and pending patent properties to fundamental Adnectin forms. In addition, Adnexus exclusively controls its patented PROfusion(TM) System. Adnexus has over 100 issued and pending patent properties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc Adnectins and PROfusion. About the New Adnectin Product Class and the PROfusion System Adnectins are an emerging protein therapeutic class that can be designed to address a broad range of diseases. They are based on human fibronectin, an extracellular extracellular /ex·tra·cel·lu·lar/ (-sel´u-lar) outside a cell or cells. ex·tra·cel·lu·lar adj. Located or occurring outside a cell or cells. protein that is naturally abundant in human serum. The intrinsic properties of an Adnectin align with the properties needed to make a successful drug, including high potency, specificity, stability, favorable half life, and high yield production. Adnectins are designed using the PROfusion System, Adnexus' patented protein design engine, to achieve high potency and specificity for a therapeutic target while simultaneously selecting for ideal pharmaceutical product characteristics. PROfusion enables Adnexus to screen over 1 trillion unique Adnectins for each target to "redirect re·di·rect tr.v. re·di·rect·ed, re·di·rect·ing, re·di·rects To change the direction or course of. n. A redirect examination. re " a naturally occurring human fibronectin to act as a protein therapeutic. This greatly accelerates Adnectin drug discovery and development. About Adnexus Therapeutics Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of its broadly applicable new therapeutic class, Adnectins. Adnexus' lead product candidate, CT-322, is in Phase 1 clinical development in oncology in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The company also has a pipeline of other Adnectin products in preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that uniquely enables rapid optimization of protein therapeutics. The company is funded by four leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] : Atlas Venture Atlas Venture is an international early-stage venture capital firm that invests in communications, information technology, and life sciences companies. Atlas Venture has investing offices in Boston, London, Munich, and Paris, and its investments are evenly divided between the , Flagship Ventures, Polaris Venture Partners, and Venrock Associates. This news release contains certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products. Adnectin[TM], Adnexus Therapeutics[TM] and PROfusion[TM] are trademarks of Adnexus Therapeutics[TM], Inc. Adnexus Therapeutics(SM) is a service mark of Adnexus Therapeutics[TM]. For more information, please visit www.adnexustx.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion